D
Apellis Pharmaceuticals, Inc. APLS
$21.92 $0.673.15% NASDAQ
Recommendation
Prev Close
$21.25
Volume
942,751
Avg Vol (90D)
2,608,627
Market Cap
$2.69B
Dividend & Yield
--
52-Week Range
$16.10 - $35.72
P/E (TTM)
68.88
EPS (TTM)
$0.31
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Apellis Pharmaceuticals (APLS) Shares Cross Above 200 DMA
12/4/2025 - Market News Video
Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue?
12/4/2025 - Zacks Investment Research
Prudential Financial Inc. Decreases Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS
12/4/2025 - MarketBeat
The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI (pegcetacoplan) for C3G and Primary IC-MPGN
12/3/2025 - Globe Newswire
Apellis Pharmaceuticals, Inc. (APLS) Presents at Evercore 8th Annual Healthcare Conference Transcript
12/3/2025 - Seeking Alpha: Transcripts
Apellis Pharmaceuticals, Inc. (APLS) Presents at Evercore 8th Annual Healthcare Conference Transcript
12/3/2025 - SeekingAlpha
Why Is Halozyme Therapeutics (HALO) Down 2.2% Since Last Earnings Report?
12/3/2025 - Zacks Investment Research
Apellis Pharmaceuticals, Inc. (APLS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
12/2/2025 - Seeking Alpha: Transcripts
Apellis Pharmaceuticals, Inc. (APLS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
12/2/2025 - SeekingAlpha
Assessing Apellis Pharmaceuticals (APLS) Valuation Following Five-Year SYFOVRE Efficacy Data in Geographic Atrophy
12/2/2025 - Simply Wall St
38,572 Shares in Apellis Pharmaceuticals, Inc. $APLS Purchased by Wealthedge Investment Advisors LLC
12/2/2025 - MarketBeat
Virtus Investment Advisers LLC Acquires 12,106 Shares of Apellis Pharmaceuticals, Inc. $APLS
12/1/2025 - MarketBeat
Apellis Post Hoc Analysis Confirms Long-Term Benefit of SYFOVRE for Geographic Atrophy
11/30/2025 - Insider Monkey
Can Revised Syfovre Projections Reshape Apellis Pharmaceuticals' (APLS) Case for Long-Term Growth?
11/28/2025 - Simply Wall St
Apellis Pharmaceuticals (APLS, $21.59) Stochastic Oscillator left the overbought zone on November 26, 2025
11/27/2025 - Tickeron - Stocks
Apellis Pharmaceuticals (APLS, $21) price may drop as it broke higher Bollinger Band on Nov 25, 2025
11/26/2025 - Tickeron - Stocks
Apellis Pharmaceuticals, Inc. $APLS Stock Position Decreased by SG Americas Securities LLC
11/26/2025 - MarketBeat
Mizuho Lowers Price Target on Apellis Pharmaceuticals (APLS) Amid Ongoing Eye Disease Therapy Challenges
11/25/2025 - Yahoo! Finance: News
Apellis Pharmaceuticals (APLS, $20.13) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 24, 2025
11/25/2025 - Tickeron - Stocks
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
11/25/2025 - GuruFocus
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
11/25/2025 - Globe Newswire
FY2025 Earnings Estimate for APLS Issued By Zacks Research
11/22/2025 - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel Sells $100,300.00 in Stock
11/19/2025 - MarketBeat
Assessing Apellis Pharmaceuticals (APLS) Valuation Following Recent Share Price Weakness
11/19/2025 - Simply Wall St
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel Sells 5,000 Shares of Stock
11/18/2025 - Ticker Report
Income Statement
Total Revenue (TTM)
$1.02B
EBITDA (TTM)
$82.08M
EBIT (TTM)
$80.41M
Net Income (TTM)
$44.99M
Balance Sheet
Total Assets (Q)
$1.06B
Total Debt (Q)
$475.37M
Total Liabilities (Q)
$657.56M
Book Value Per Share (Q)
$3.17
Cash Flow
Cash from Operations (TTM)
$78.86M
Cash from Investing (TTM)
-$225.00K
Cash from Financing (TTM)
$3.63M
Net Change in Cash (TTM)
$82.36M
Filings
Filing Date
Thursday, October 30, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
0.91
7-Day Total Return
8.89%
30-Day Total Return
-22.10%
60-Day Total Return
-15.82%
90-Day Total Return
15.67%
Year to Date Total Return
-33.90%
1-Year Total Return
-35.77%
2-Year Total Return
-65.68%
3-Year Total Return
-55.61%
5-Year Total Return
-56.12%
52-week Low
May 15, 2025 - $16.10
52-week High
Dec 09, 2024 - $35.72
Valuation
Market Cap
$2.69B - Mid Cap
Enterprise Value
$2.68B
Price/Sales (TTM)
2.72
Price/Book (Q)
6.70
Dividends and Shares
Shares Outstanding
130.07
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
apellis.com
Phone Number
617 977 5700
Address
100 Fifth Avenue
Waltham, MA 02451
Country
United States
Year Founded
2009
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with... more
NASDAQ 12/04/2025 12:50PM Eastern Quotes delayed